Fig. 4: AR suppression upregulates OPRK1, which underpin androgen-independent growth of androgen-independent derivatives of LNCaP cells. | Communications Biology

Fig. 4: AR suppression upregulates OPRK1, which underpin androgen-independent growth of androgen-independent derivatives of LNCaP cells.

From: Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1

Fig. 4

a, b Expressions of AR in LNCaP, AILNCaP2 (AI2), AILNCaP3 (AI3), and AILNCaP4 (AI4) treated with siRNA for GFP (siControl) and AR (siAR#1 and siAR#2) assessed by quantitative RT-PCR (a) and western blot (b). **P < 0.01, Normalized by GAPDH (a) and β-actin (ACTB, b). c Expression of OPRK1 in LNCaP, AILNCaP2 (AI2), AILNCaP3 (AI3), and AILNCaP4 (AI4) treated with siRNA for GFP (siControl) and AR (siAR#1 and siAR#2) assessed by quantitative RT-PCR. **P < 0.01, Normalized by GAPDH. d Expression of AR (left) and OPRK1 (right) in LNCaP cultured in media supplemented with 10%FBS, charcoal-stripped FBS (CSFBS), and CSFBS plus 1 nM dihydrotestosterone. **P < 0.01, Normalized by GAPDH. e Chromatin immunoprecipitation (ChIP) using anti-AR antibody and control IgG followed by quantitative RT-PCR using two primers for OPRK1 promoter (OPRK1-a, and -b) in LNCaP cells cultured as in d. **P < 0.01. f, g ChIP using anti-AR antibody and control IgG followed by quantitative RT-PCR using two primers for OPRK1 promoter (OPRK1-a, and -b) in KUCaP2 AD (f) and CR (g) tumors. **P < 0.01. h Expression of AR in LNCaP, AILNCaP2 (AI2), AILNCaP3 (AI3), and AILNCaP4 (AI4) treated with siRNA for GFP (siControl) and OPRK1 (siOPRK1#1 and siOPRK1#2) assessed by quantitative RT-PCR. Normalized by GAPDH. i Expression of ORPK1 normalized by GAPDH (left) and cell proliferation (right) in LNCaP, AILNCaP2 (AI2), AILNCaP3 (AI3), and AILNCaP4 (AI4) treated with siRNA for GFP (siControl) and OPRK1 (siOPRK1#1 and siOPRK1#2). *P < 0.05, **P < 0.01. j Summarized cell proliferation rates of indicated cells with regard to the concentration of supplemented nor-BNI, OPRK1 inhibitor. *P < 0.05.

Back to article page